A5049114495- Inflammatory Bowel Disease
- Microscopic Colitis
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
- COVID-19 and healthcare impacts
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Diagnosis and treatment of tuberculosis
- Tuberculosis Research and Epidemiology
- Diverticular Disease and Complications
- Pregnancy and Medication Impact
- Liver Diseases and Immunity
- Gut microbiota and health
- Eosinophilic Esophagitis
- Intestinal Malrotation and Obstruction Disorders
- Appendicitis Diagnosis and Management
- S100 Proteins and Annexins
- Vibrio bacteria research studies
- Psoriasis: Treatment and Pathogenesis
- Gastrointestinal motility and disorders
- Infant Nutrition and Health
- SARS-CoV-2 and COVID-19 Research
- Alcoholism and Thiamine Deficiency
- Cancer Immunotherapy and Biomarkers
- Pancreatitis Pathology and Treatment
Hvidovre Hospital
2016-2025
Copenhagen University Hospital
2014-2025
University of Copenhagen
2020-2022
Amager Hospital
2008-2014
Capital Region of Denmark
2014
Gentofte Hospital
2011
Mucosal healing in ulcerative colitis leads to a decreased need for medication and risk of disease relapse colectomy. Histological seems improve the prognosis even further. An assessment both endoscopic histological mucosal requires endoscopy, reliable noninvasive biomarker predict is obvious.Seventy patients were included followed up 12 months. Inclusion criteria total Mayo score ≤1 = 0. The underwent sigmoidoscopy with rectal biopsies. Fecal calprotectin (FC) was measured 2 3 days before...
As no population-based study has investigated the susceptibility and disease course of COVID-19 among patients with inflammatory bowel diseases [IBD], we aimed to investigate this topic in a setting.Two cohorts were investigated. First, nationwide cohort all IBD diagnosed was prospectively followed courses both diseases. Second, within 2.6 million Danish citizens, identified individuals tested for SARS-CoV-2 determine occurrence without other immune-mediated [IMIDs].Between January 28, 2020...
Abstract Background Low-dose azathioprine in combination with allopurinol (LD-AZA/ALLO) is a widely used treatment option inflammatory bowel disease (IBD). Data on pregnancy and birth outcomes from exposure to therapy are sparse. The aim of this study was provide data safety risk for adverse women IBD treated LD-AZA/ALLO at the Gastrounit, Hvidovre Hospital, Copenhagen. Methods retrospective single center study. Inclusion criteria were established diagnosis (AZA 50-75 mg/ ALLO 100 mg) during...
Retrospective studies suggest that for patients with ulcerative colitis (UC) combination therapy low-dose azathioprine and allopurinol (L-AZA/ALLO) may result in higher remission rates than monotherapy (AZA). We prospectively investigated the effects of these drugs moderate-to-severe UC.
Health-related quality of life [HRQoL] is impaired in ulcerative colitis and correlated to clinical disease activity. The recent shift towards more objective treatment goals like mucosal healing generates a need for evaluating the association between endoscopic activity, HRQoL. In this cross-sectional study, patients with either active or inactive underwent sigmoidoscopy. Clinical activity was assessed by Simple Colitis Activity Index [SCCAI], inflammation Mayo Endoscopic Subscore [MES],...
This study assesses the prognostic role of intestinal ultrasound (IUS) in determining disease course ulcerative colitis (UC) first year after diagnosis. A prospective, multicenter population-based inception-cohort was conducted on patients newly diagnosed with UC. Patients left-sided or extensive UC underwent IUS assessments at diagnosis, three months, and 12 alongside symptomatic, biochemical, endoscopic evaluations. Transmural remission defined as bowel wall thickness ≤ 3 mm without color...
Background: Treating inflammatory bowel diseases (IBD) using thiopurines is effective; however, a high rate of adverse effects and lack efficacy limit its use. Retrospective studies have suggested that treatment with low-dose in combination allopurinol associated higher remission rates lower incidence events.Aim: To compare the clinical events IBD patients treated either standard azathioprine or allopurinol.Methods: A prospective, open-label study, randomizing thiopurine-naïve normal...
Introduction Inflammatory bowel diseases (IBD), encompassing Crohn’s disease and ulcerative colitis, are chronic, inflammatory of the gastrointestinal tract. We have initiated a Danish population-based inception cohort study aiming to investigate underlying mechanisms for heterogeneous course IBD, including need for, response to, treatment. Methods analysis IBD Prognosis Study is prospective, unselected, newly diagnosed adult, adolescent paediatric patients with within uptake area Hvidovre...
Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and tailor medical treatment activity. Laboratory testing fecal samples may have a turnaround time 1-2 weeks, whereas FC home allows results within hours thus enables rapid response clinical deterioration.Fifty-five stool were analyzed by IBDoc® Calprotectin Home Testing kit BÜHLMANN fCAL® turbo assay on Roche Cobas 6000 c501. The correlation between assays was assessed using Spearman's Rho...
The health consequences of coronavirus disease 2019 [COVID-19] among patients with ulcerative colitis [UC] and Crohn's [CD] remain largely unknown. We aimed to investigate the outcomes long-term effects COVID-19 in UC or CD.We conducted a prospective, population-based study covering all Danish CD confirmed between January 28, 2020 April 1, 2021, through medical records questionnaires.All 319 197 who developed Denmark were included this compared background population [N = 230 087]. A...
Objective. Monitoring active ulcerative colitis (UC) is essential for making correct and timely treatment decisions. The current monitoring based on symptom scores biochemical markers, among which the role of fecal calprotectin (FC) debated. aims were to assess development in FC during steroid compare with markers. Material methods. A prospective observational study, including 16 patients UC requiring high-dose treatment. FC, C-reactive protein (CRP), leukocytes, hemoglobin, albumin, simple...
Thiopurine and allopurinol in combination are associated with clinical remission inflammatory bowel diseases but their influence on subsequent outcomes is unclear. We compared during exposure to both thiopurines versus alone.We established a nationwide cohort of patients exposed ± 1999-2014, using registry data. Patients were followed until hospitalization, surgery, anti-TNFα, or death (as primary composite outcome). used Poisson regression analyses calculate incidence rate ratios overall...
Objective The long-term outcome of thiopurine therapy in patients with ulcerative colitis (UC) enrolled prospective trials have not been evaluated. We aimed to assess the effects optimised maintenance for UC.
Abstract Background The disease course of inflammatory bowel (IBD) is heterogeneous and unpredictable. Currently, we are unable to predict which patients will need IBD-related resection in the first year after diagnosis. Intestinal Ultrasound (IUS) has been proven as a non-invasive modality for assessing activity IBD. However, evidence IUS predictor still limited. Here present novel data on predictive value performed at time IBD Methods Patients with new-onset currently being included...
Two meta-analyses have found that the risk of relapse in Crohn's disease (CD) was ~40 and 50% 1 2 years, respectively, after withdrawal anti-tumour necrosis factor-α (anti-TNFα). The aim this study to evaluate rates CD when thiopurine therapy optimized before anti-TNFα withdrawal.An observational conducted including patients with remission withdrawal. We defined as 6-thioguanine levels at least 150 nmol/mmol haemoglobin (∼300 pmol×10 red blood cells) clinical/biochemical Harvey-Bradshaw...
Common variable immunodeficiency (CVID) is the most frequent primary immunodeficiency, characterized by reduced levels of immunoglobulins [1] [2]. Due to a heterogeneous presentation including heightened rate infections, diagnosis often delayed for 4 – 9 years. This delay may contribute increased morbidity and mortality in CVID patients [3].
Patients with inflammatory bowel disease (IBD) who receive biologicals frequently experience lack or loss of response. Our aim was to describe the use and efficacy biological therapy in a tertiary IBD center.We included all bio-naive patients initiated between 2010 2020 at our centre. Their medical records were reviewed.The population consisted 327 Crohn's (CD) patients, 291 ulcerative colitis (UC) 3 unclassified (IBDU). The median follow-up years (interquartile range = 2-5) after initiating...